Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study

Martin J. van den Bent(Erasmus MC Cancer Institute), E. Raymond(European Organisation for Research and Treatment of Cancer), P. Fumoleau(Institut Curie), Bruno Coudert(Ludwig Boltzmann Institute for Cancer Research), Roger Stupp(Northwestern University), Michel Frenay(European Organisation for Research and Treatment of Cancer), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Paul M. Clément(Universitair Ziekenhuis Leuven), Denis Lacombe(European Organisation for Research and Treatment of Cancer), Christian Dittrich(Leibniz Institute for Agricultural Engineering and Bioeconomy)
Journal of Clinical Oncology
June 1, 2005
10.1200/jco.2005.23.16_suppl.1517
Cited by 17

Related Papers

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
|JAMA|2017|2.5k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k